CVS Health Corporation

05/18/2026 | Press release | Distributed by Public on 05/18/2026 14:14

Proxy Results, Management Change/Compensation (Form 8-K)

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
(e) On May 14, 2026, CVS Health Corporation (the "Company") held its 2026 Annual Meeting of Stockholders (the "Annual Meeting"). At the Annual Meeting, the Company's stockholders approved the 2026 Incentive Compensation Plan of CVS Health Corporation (the "2026 ICP"), which replaces the Company's expiring 2017 Incentive Compensation Plan. The 2026 ICP applies to awards granted after May 14, 2026. The Management Planning and Development Committee and the Board of Directors of the Company previously approved the 2026 ICP, subject to stockholder approval.
For a description of the principal terms of the 2026 ICP, see "Item 4: Proposal to Approve the Company's 2026 Incentive Compensation Plan" in the Company's Proxy Statement for the Annual Meeting filed with the Securities and Exchange Commission on April 3, 2026 (the "Proxy Statement"), which description is incorporated herein by reference. A complete copy of the 2026 ICP was included as Annex B to the Proxy Statement and is incorporated herein by reference.
Item 5.07 Submission of Matters to a Vote of Security Holders.
As noted above, the Company's Annual Meeting was held on May 14, 2026. The following are the voting results on each matter submitted to the stockholders of the Company at the Annual Meeting. The proposals below are described in detail in the Proxy Statement. There were present at the Annual Meeting, in person or by valid proxy, the holders of 1,142,802,406 shares of the Company's common stock, constituting a quorum.
At the Annual Meeting, the 13 nominees for director were elected to the Company's Board of Directors for a term of one year (Item 1). The Company proposal regarding the ratification of the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for 2026 (Item 2) was approved. The Company proposal to approve, on an advisory basis, the compensation of the Company's named executive officers as disclosed in the Proxy Statement (Item 3) was approved. The Company proposal to approve the Company's 2026 ICP (Item 4) was approved. One stockholder proposal (Item 5) was not approved.
Item For Against Abstained Broker Non-Votes
1. The election, for one-year terms, of persons nominated for election as directors of the Company, as set forth in the Company's Proxy Statement, was approved by the following votes:
Fernando Aguirre 1,022,555,114 14,973,034 1,190,326 104,083,932
Jeffrey R. Balser, M.D., Ph.D. 1,027,705,454 9,787,711 1,225,309 104,083,932
C. David Brown II 963,381,905 74,082,639 1,253,930 104,083,932
Alecia A. DeCoudreaux 996,234,731 41,326,102 1,157,641 104,083,932
Anne M. Finucane 1,010,527,586 27,032,194 1,158,694 104,083,932
John E. Gallina 1,024,886,453 12,566,628 1,265,393 104,083,932
J. David Joyner 968,110,706 66,554,762 4,053,006 104,083,932
J. Scott Kirby 995,832,249 41,667,652 1,218,573 104,083,932
Michael F. Mahoney 940,279,615 96,450,126 1,988,733 104,083,932
Leslie V. Norwalk 1,021,952,646 15,580,839 1,184,989 104,083,932
Larry M. Robbins 1,026,332,859 11,150,192 1,235,423 104,083,932
Guy P. Sansone 995,433,957 42,056,031 1,228,486 104,083,932
Douglas H. Shulman 1,020,665,806 16,793,215 1,259,453 104,083,932
2. Company proposal to ratify the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for 2026, as set forth in the Company's Proxy Statement, was approved by the following vote: 1,117,411,640 24,102,167 1,288,599 None
3. Company proposal to approve, on an advisory basis, the compensation of the Company's named executive officers, as set forth in the Company's Proxy Statement, was approved by the following vote: 976,252,194 59,088,923 3,377,357 104,083,932
4. Company proposal to approve the Company's 2026 Incentive Compensation Plan, as set forth in the Company's Proxy Statement, was approved by the following vote: 1,006,709,390 28,851,289 3,157,795 104,083,932
5. Stockholder proposal for reducing the threshold for the Company's stockholder right to act by written consent, as set forth in the Company's Proxy Statement, was not approved by the following vote: 417,969,177 617,361,014 3,388,283 104,083,932
CVS Health Corporation published this content on May 18, 2026, and is solely responsible for the information contained herein. Distributed via EDGAR on May 18, 2026 at 20:14 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]